SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Can-Fite Says Namodenoson Meets Phase IIa Trial Safety Endpoint

Can-Fite said namodenoson met the safety endpoint in a Phase IIa pancreatic cancer trial.

Related stories